TY - JOUR
T1 - Underutilization of evidence-based smoking cessation support strategies despite high smoking addiction burden in peripheral artery disease specialty care
T2 - Insights from the international PORTRAIT registry
AU - Patel, Krishna K.
AU - Jones, Philip G.
AU - Ellerbeck, Edward F.
AU - Buchanan, Donna M.
AU - Chan, Paul S.
AU - Pacheco, Christina M.
AU - Moneta, Gregory
AU - Spertus, John A.
AU - Smolderen, Kim G.
N1 - Funding Information:
The research reported in this manuscript was partially funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (IP2 PI000753-01; CE-1304-6677), the Netherlands Organization for Scientific Research (VENI Grant No. 916.11.179), and an unrestricted grant from W. L. Gore & Associates, Inc (Flagstaff, AZ). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The statements in this manuscript are solely the responsibility of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors, or Methodology Committee. All manuscripts for the PORTRAIT study are prepared by independent authors who are not governed by the funding sponsors and are reviewed by an academic publications committee before submission. The funding
Funding Information:
Dr Patel is supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Number T32HL110837. Dr Chan is supported by funding (R01HL123980) from the National Heart Lung and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Dr Ellerbeck is supported by NIH and PCORI for smoking cessation related research. Dr Spertus owns copyright for the Peripheral Artery Questionnaire. He serves as a consultant to United Healthcare, Bayer, and Novartis (modest). He has research grants from Abbott Vascular, Novarits and is the PI of an analytic center for the American College of Cardiology (significant). He has an equity interest in Health Outcomes Sciences (significant). Dr Smolderen is supported by an unrestricted research grant by Merck and Boston Scientific. The remaining authors have no disclosures to report.
Publisher Copyright:
© 2018 The Authors.
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Background-—Smoking is the most important risk factor for peripheral artery disease (PAD). Smoking cessation is key in PAD management. We aimed to examine smoking rates and smoking cessation interventions offered to patients with PAD consulting a vascular specialty clinic; and assess changes in smoking behavior over the year following initial visit. Methods and Results-—A total of 1272 patients with PAD and new or worsening claudication were enrolled at 16 vascular specialty clinics (2011–2015, PORTRAIT (Patient-Centered Outcomes Related to Treatment Practices in Peripheral Arterial Disease: Investigating Trajectories) registry). Interviews collected smoking status and cessation interventions at baseline, 3, 6, and 12 months. Among smokers, transition state models analyzed smoking transitions at each time point and identified factors associated with quitting and relapse. On presentation, 474 (37.3%) patients were active, 660 (51.9%) former, and 138 (10.8%) never smokers. Among active smokers, only 16% were referred to cessation counseling and 11% were prescribed pharmacologic treatment. At 3 months, the probability of quitting smoking was 21%; among those continuing to smoke at 3 months, the probability of quitting during the next 9 months varied between 11% and 12% (P<0.001). The probability of relapse among initial quitters was 36%. At 12 months, 72% of all smokers continued to smoke. Conclusions-—More than one third of patients with claudication consulting a PAD provider are active smokers and few received evidence-based cessation interventions. Patients appear to be most likely to quit early in their treatment course, but many quickly relapse and 72% of all patients smoking at baseline are still smoking at 12 months. Better strategies are needed to provide continuous cessation support.
AB - Background-—Smoking is the most important risk factor for peripheral artery disease (PAD). Smoking cessation is key in PAD management. We aimed to examine smoking rates and smoking cessation interventions offered to patients with PAD consulting a vascular specialty clinic; and assess changes in smoking behavior over the year following initial visit. Methods and Results-—A total of 1272 patients with PAD and new or worsening claudication were enrolled at 16 vascular specialty clinics (2011–2015, PORTRAIT (Patient-Centered Outcomes Related to Treatment Practices in Peripheral Arterial Disease: Investigating Trajectories) registry). Interviews collected smoking status and cessation interventions at baseline, 3, 6, and 12 months. Among smokers, transition state models analyzed smoking transitions at each time point and identified factors associated with quitting and relapse. On presentation, 474 (37.3%) patients were active, 660 (51.9%) former, and 138 (10.8%) never smokers. Among active smokers, only 16% were referred to cessation counseling and 11% were prescribed pharmacologic treatment. At 3 months, the probability of quitting smoking was 21%; among those continuing to smoke at 3 months, the probability of quitting during the next 9 months varied between 11% and 12% (P<0.001). The probability of relapse among initial quitters was 36%. At 12 months, 72% of all smokers continued to smoke. Conclusions-—More than one third of patients with claudication consulting a PAD provider are active smokers and few received evidence-based cessation interventions. Patients appear to be most likely to quit early in their treatment course, but many quickly relapse and 72% of all patients smoking at baseline are still smoking at 12 months. Better strategies are needed to provide continuous cessation support.
KW - Peripheral arterial disease
KW - Smoking
UR - http://www.scopus.com/inward/record.url?scp=85055612289&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055612289&partnerID=8YFLogxK
U2 - 10.1161/JAHA.118.010076
DO - 10.1161/JAHA.118.010076
M3 - Article
C2 - 30371269
AN - SCOPUS:85055612289
SN - 2047-9980
VL - 7
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 20
M1 - e010076
ER -